2,3-dibromo-6-hydroxy-5-methoxybenzaldehyde | 20035-42-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2,3-dibromo-6-hydroxy-5-methoxybenzaldehyde
• CAS: 20035-42-1
• 化学式: C₈H₆Br₂O₃
• mdl: MFCD00046151
• 分子量: 309.942
• InChiKey: NEQRDPRMCZPVJM-UHFFFAOYSA-N

物化性质

• 沸点：
  322.5±37.0 °C(Predicted)
• 密度：
  1.988±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,3-dibromo-6-hydroxy-5-methoxybenzaldehyde 在 sodium hydroxide 、 silver(l) oxide 作用下， 生成 5,6-Dibrom-o-vanillinsaeure
  参考文献：
  名称：

  “远距离” -kopplungen在einigen kernsubstituierten Ø -hydroxyanisolen UND verwandten verbindungen

  摘要：

  研究了某些取代的2-羟基苯甲醚衍生物中苯基质子与链质子之间的长距离偶合，尤其是OCH 3，CH 2 OH和CH = CH.CO.CH 3。

  DOI：

  10.1016/0040-4020(72)84037-7

文献信息

• 단백질 티로신 키나아제를 저해하는 화합물 및 이것을 포함하는 암의 치료용 또는 예방용 약학 조성물
  申请人：UIF (University Industry Foundation), Yonsei University 연세대학교 산학협력단(220050095099) BRN ▼110-82-10500

  公开号：KR101639289B1

  公开（公告）日：2016-07-13

  본 발명은 신규 화합물 및 이것의 제조방법에 관한 것으로서, 특히 단백질 티로신 키나아제의 비정상적 활성과 관련된 질환을 치료 또는 예방할 수 있는 약학 조성물에 관한 것이다.

  本发明涉及一种新化合物及其制备方法，特别是涉及一种药学组合物，可以治疗或预防与蛋白酪氨酸激酶异常活性相关的疾病。
• IRE-1alpha INHIBITORS
  申请人：MannKind Corporation

  公开号：US20140080832A1

  公开（公告）日：2014-03-20

  Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.

  直接抑制IRE-1α活性的化合物、前药及其药学上可接受的盐。这些化合物和前药可用于治疗与未折叠蛋白应答相关的疾病，并可作为单一药物或联合治疗的组分。
• Discovery of ( E )-5-(benzylideneamino)-1 H -benzo[ d ]imidazol-2(3 H )-one derivatives as inhibitors for PTK6
  作者：Hyun Jae Shim、Hye Ran Yang、Han Ie Kim、Shin-Ae Kang、Kyoung Tai No、Young Hoon Jung、Seung-Taek Lee

  DOI：10.1016/j.bmcl.2014.08.036

  日期：2014.10

  A lead compound 1, which inhibits the catalytic activity of PTK6, was selected from a chemical library. Derivatives of compound 1 were synthesized and analyzed for inhibitory activity against PTK6 in vitro and at the cellular level. Selected compounds were analyzed for cytotoxicity in human foreskin fibroblasts using MTT assays and for selectivity towards PTK members in HEK 293 cells. Compounds 20 (in vitro IC50=0.12μM) and 21 (in vitro IC50=0.52μM) showed little cytotoxicity, excellent inhibition of PTK6 in vitro and at the cellular level, and selectivity for PTK6. Compounds 20 and 21 inhibited phosphorylation of specific PTK6 substrates in HEK293 cells. Thus, we have identified novel PTK6 inhibitors that may be used as treatments for PTK6-positive carcinomas, including breast cancer.
• IRE-1A INHIBITORS
  申请人：MannKind Corporation

  公开号：EP2155643B1

  公开（公告）日：2016-08-10
• IRE-1alpha Inhibitors
  申请人：MannKind Corporation

  公开号：US20160168116A1

  公开（公告）日：2016-06-16

  Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.